NCT04822350 2026-04-02
AVENANCE
Pfizer
Completed
Clinical Trials
38 trialsNCT03006848 2026-02-23
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT05366725 2025-12-02
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03724890 2025-04-10
Study of Avelumab-M3814 Combinations
EMD Serono
Phase 1 Completed
NCT05431777 2025-04-01
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT05650164 2025-03-28
J-DART2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT02576574 2025-01-31
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono
Phase 3 Completed
NCT04682587 2025-01-03
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Pfizer
Completed
NCT04068831 2024-12-27
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03990571 2024-10-18
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04173507 2024-09-03
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Completed
NCT03046953 2024-07-16
AVAIL-T
University of Birmingham
Phase 2 Completed
NCT03558139 2024-04-01
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Gilead Sciences
Phase 1 Completed
NCT02603432 2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3 Completed
NCT02155647 2024-03-13
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
Phase 2 Completed
NCT03523390 2024-02-23
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03892642 2024-02-14
OU-SCC-ABC
University of Oklahoma
Phase 1/2 Completed
NCT02915523 2024-01-10
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT05012865 2023-12-06
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
Completed
NCT03399552 2023-10-23
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03390296 2023-09-05
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT03905135 2022-09-13
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02968940 2022-06-29
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
NYU Langone Health
Phase 2 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT03717155 2022-06-06
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT01772004 2021-12-20
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
EMD Serono
Phase 1 Completed
NCT03179410 2021-03-05
PICK-NEPC
Duke University
Phase 2 Completed
NCT02222922 2020-12-17
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT03704467 2020-11-13
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
EMD Serono
Phase 1 Completed
NCT01943461 2020-09-30
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03289533 2020-09-04
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Pfizer
Phase 1 Completed
NCT02395172 2020-08-03
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
EMD Serono
Phase 3 Completed